Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: To provide an overview of the implementation of the mortality study, and to exchange information among government, stakeholders, and interested parties on procedural and related aspects of the study.

Matters To Be Discussed: The agenda will include information on the NIOSH/NCI research plan; request for information on industrial hygiene sample measurements or other data, or possible sources of such data that could add to the study validity; request for information on types and usage of diesel engines and fuel of relevance to exposure estimation; plan for data sharing and announcement of future informational meetings. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited. Written comments will also be considered.

Contact Person For Additional Information: Michael Attfield, Ph.D., NIOSH Project Director, Division of Respiratory Disease Studies, NIOSH, CDC, M/S 234, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888, telephone 304/285–5737, E-mail mda1@cdc.gov.

Individuals wishing to make an oral statement should contact Dr. Attfield so that time can be allocated.

Dated: August 19, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–22469 Filed 8–21–97; 8:45 am]

BILLING CODE 4160–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee

National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and the Advisory Commission on Childhood Vaccines (ACCV) Subcommittee on Vaccine Safety: Meetings.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.–12:30 p.m., September 8, 1997; 8:30 a.m.–12 noon, September 9, 1997.

Place: Hubert H. Humphrey Building, Room 303A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Purpose: This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters To Be Discussed: Agenda items will include a National Vaccine Program Office (NVPO) update; discussions on immunization coverage: Strategies to sustain success; accountability for immunization: Closing the gaps; immunization registries: Workshop plans; vaccine safety datalink: Local and national perspectives; surveillance for adverse events following vaccination: Options for funding; mucosal vaccines: Status, potential and current research; utilization of non-traditional sites for adult immunization; IPV/OPV: Impact of revised recommendations on coverage; clarifying harmonization of package labeling and recommendations of advisory groups. There will be an update on plans to address concerns following the Edmonston-Zagreb Measles Vaccine Investigation in Los Angeles, California. Also, there will be reports from the work group on philosophic objections; reports from the Subcommittee on Immunization Coverage; Subcommittee on Future Vaccines; and the Subcommittee on Vaccine Safety.

Name: Subcommittee on Immunization Coverage.

Time and Date: 1:30 p.m.–5 p.m., September 8, 1997.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters To Be Discussed: This subcommittee will hold a discussion on the review of recommendations from the document, ''Strategies to Sustain Immunization Coverage'', and the finalization of those recommendations.

Name: Subcommittee on Future Vaccines.

Time And Date: 1:30 p.m.–5 p.m., September 8, 1997.

Place: Hubert H. Humphrey Building, Room 405A, 00 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

Matters To Be Discussed: This subcommittee will hold discussions regarding the Cold Spring Harbor Report; combination vaccines, strategic options; and defining future vaccines policy issues for traveler's vaccines.

Name: Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines, Subcommittee on Vaccine Safety.

Time And Date: 1:15 p.m.–4:45 p.m., September 9, 1997.

Place: Hubert H. Humphrey Building, Room 303A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This joint NVAC/ACCV subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

Matters To Be Discussed: This subcommittee will hold discussions regarding the vaccine safety subcommittee goals; a report from the Task Force on Safer Childhood Vaccines; a project report on benefit-risk communication curriculum development; and agenda items for next meeting.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639–7250.

Dated: August 18, 1997.

Nancy C. Hirsch,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–22470 Filed 8–21–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Notice of Lien.

OMB No.: 0970–0153.

Description: Section 324 of PRWORA '96 (Pub. L. 104–193), requires DHHS to promulgate a standard lien form for use by the State CSE programs to secure delinquent child support obligations in interstate cases.

Respondents: States.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Lien	53,254	1	0.25	13,313

Estimated Total Annual Burden Hours: 13,313.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: August 18, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–22285 Filed 8–21–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Administrative Subpoena.

OMB No.: 0970–0152.

Description:

Respondents: Individuals and Households; not-for-profit institutions; business or other for-profit; and State, Local or Tribal Govt.

Annual Burden Estimates:

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Subpoena	15,391	1	0.5	7,696

Estimated Total Annual Burden Hours: 7,696.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, NW., Washington, DC 20503, Attn: Ms. Wendy Taylor.

Dated: August 18, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–22286 Filed 8–21–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 15, 1997, 10 a.m. to 5:30 p.m., and September 16, 1997, 8 a.m. to 12 m.

Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Martha T. O'Lone, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8913, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12520. Please call the Information Line for up-to-date information on this meeting.

Agenda: On September 15 and 16, 1997, the committee will discuss and make recommendations on the draft guidance entitled ''Testing for Skin Sensitization to Chemicals in Latex Products.'' Single copies of this draft guidance are available to the public from the Division of Small Manufacturers Assistance, 1350 Piccard Dr., Rockville, MD 20851, 1-800-638-2041, or on the Internet using the World Wide Web (WWW) (http://www.fda.gov/cdrh/draftgui.html).

Procedure: On September 15, 1997, from 10:30 a.m. to 5:30 p.m., and September 16, 1997, from 8 a.m. to 12 m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by August 9, 1997. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 m. on September 15, 1997. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact